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Abstract
The transforming growth factorB (TGFB) superfamily
regulates a broad spectrum of biological responses
throughout embryonic development and adult life,
including cell proliferation and differentiation, epithelial-
to-mesenchymal transition, apoptosis, and angio-
genesis. TGFB members initiate signaling by bringing
together a complex of serine/threonine kinase receptors
that transmit signals through intracellular Smad pro-
teins. Genetic alterations in numerous components of
the TGFB signaling pathway have been associated with
several human cancers. In addition, tight regulation of
TGFB signaling is pivotal to the maintenance of homeo-
stasis and the prevention of carcinogenesis. The ubiq-
uitin/proteosome system is one mechanism by which
cells regulate the expression and activity of effectors of
the TGFB signaling cascade. Mounting evidence also
suggests that disruption of the ubiquitin-dependent
degradation of components of the TGFB pathway leads
to the development and progression of cancer. There-
fore, understanding how these two pathways intertwine
will contribute to the advancement of our knowledge of
cancer development.
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Introduction
The transforming growth factor b (TGFb) superfamily is a
large family ofmultifunctional cytokines involved in a number
of biological responses during embryonic development and
adult tissue homeostasis [1,2]. Because it promotes cell
growth inhibition, apoptosis, and differentiation, TGFb has
been described as a potent tumor suppressor [3,4]. Support-
ing this notion, mutations in the components of the TGFb
signaling cascade have been identified in a number of
human cancers, including hereditary nonpolyposis colon
cancer, hepatocellular carcinoma (HCC), and pancreatic
and ovarian cancers [5]. TGFb also functions as a tumor
promoter by stimulating angiogenesis, immunosuppression,
and epithelial-to-mesenchymal transition (EMT) in later
stages of the disease [4,6]. In recent years, ubiquitin-
dependent proteosomal degradation has proven to be an
important mechanism by which cells control TGFb signaling
output. Therefore, it is likely that disruptions in the proteo-
somal degradation of TGFb pathway components may
promote the development and progression of tumors. This
review will focus on how the TGFb signaling cascade is regu-
lated by the ubiquitin/proteosome pathway and how deregula-
tion of this may contribute to cancer.
The TGFB Signaling Pathway
TGFb is the prototypic member of the TGFb superfamily, which
also includes activins, nodals, bone morphogenetic proteins
(BMPs), and anti-Mu¨llerian factor. The cytokines signal through
a heteromeric complex of type I and type II serine/threonine
kinase receptors. Activation of the receptor complex through
ligand binding results in the phosphorylation of the type I
receptor by the type II receptor kinase [1–3,7,8]. Subsequently,
active type I receptors transiently interact with and phosphory-
late receptor-regulated Smads (R-Smads), which are intra-
cellular transducers of TGFb signals. The specificity of TGFb
or BMP responses is dictated by the ability of BMP type I
receptors to phosphorylate and activate the R-Smads, Smad1,
Smad5, and Smad8, whereas TGFb or activin type I receptors
phosphorylate the R-Smads, Smad2 and Smad3. Phosphory-
lated R-Smads then associate with Smad4, the common Smad
(co-Smad), and shuttle to the nucleus [1,2,7–9]. By interacting
with a large repertoire of transcription factors such as FoxH1,
Mixer, LEF-1/TCF, OAZ, GATA-4, or Runx-related proteins, and
cofactors such as CBP/p300, c-ski, SnoN, and histone deacet-
ylases (HDACs), Smads either positively or negatively regulate
specific transcriptional responses to TGFb and BMP signaling
[1,2,7–9]. A third class of Smads—the inhibitory Smads
(I-Smads), which include Smad6 and Smad7—has been iden-
tified as negative regulators of TGFb and BMP signaling. By
interacting with type I receptors, I-Smads block the access of
R-Smads to their specific receptors and inhibit signaling. In
addition, I-Smads can downregulate signaling by targeting cell
surface receptors for ubiquitin-dependent proteosomal degra-
dation [1,2,7–9].
Smads contain two well-conserved globular domains known
asMH1andMH2domains, which are coupled to each other by a
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divergent proline-rich linker region [1,2,7–9]. Although the C-
terminal MH2 domain is highly conserved across all Smads,
the amino-terminal domain of I-Smads shows only a weak
sequence similarity to the N-terminal MH1 domain of other
Smads. Both the MH1 and MH2 domains interact with tran-
scription factors, but only the MH1 domain is able to directly
interact with DNA [1,2,7–9]. Furthermore, the MH1 domain
contains nuclear localization signals and plays a pivotal role
in the nuclear shuttling of Smads [10]. In addition tomediating
association with DNA-binding partners, the MH2 is crucial
for Smad oligomerization and receptor interaction. It has
also been shown to mediate the interaction between Smad2
and Smad3 with the Smad anchor for receptor activation
(SARA). This FYVE domain-containing protein, which is
mainly localized into early endosomes, enhances the recruit-
ment of R-Smads to TGFb receptors and facilitates TGFb
signaling [11]. Although the linker region is less conserved
among Smads, this region comprises a PY motif that medi-
ates the recruitment of E3 ubiquitin ligases and a number of
phosphorylation sites that are important for crosstalk with
other signaling pathways, such as receptor tyrosine kinase–
mediated pathways [8,12].
Smads are the classic intracellular effectors of TGFb
signaling; however, mounting evidence shows that biological
responses can also be elicited through Smad-independent
pathways [12]. Furthermore, there is evidence demonstrat-
ing that TGFbs and BMPs can signal through MAP kinases
(such as ERK, JNK, and p38), PKB/Akt, and LIM kinase 1
[12]. More recently, TGFb signaling has been shown to
regulate EMTand cell migration through PAR6, an important
component of the epithelial polarity complex and a regulator
of tight junction assembly [13].
Ubiquitin-Dependent Regulation of R-Smads
R-Smads play a pivotal role in the transmission of TGFb/
BMP signaling, and their degradation through the ubiquitin-
dependent proteosomal pathway is an important mechanism
by which cells tightly control Smad steady-state levels and
activity. [14]. Ubiquitination occurs through a three-step pro-
cess involving ubiquitin-activating (E1), ubiquitin-conjugating
(E2), and ubiquitin ligase (E3) enzymes [15]. E3 ubiquitin
ligases are generally divided into three classes: HECT
(homologous to the E6-associated protein C-terminus) type,
RING (really interesting gene) type, and U-box type [15].
Although HECT domain–containing E3 ligases directly cat-
alyze the transfer of ubiquitin to the substrate, RING and
U-box domain E3 ligases act as molecular scaffolds that
facilitate the ubiquitination of target proteins [15]. Although
structurally related, the U-box domain differs from the RING
finger domain, as it uses hydrogen bonds, instead of zinc
binding, to stabilize its structure [16].
Smad ubiquitination–related factor 1 (Smurf1) was the
first E3 ubiquitin ligase of the C2/WW/HECT domain class to
be identified as a regulator of TGFb/BMP signaling (Figure 1,
Table 1) [17]. It was shown to target noninducedBMP-specific
Smad1 and Smad5 for degradation through a specific inter-
action between the Smurf1 WW domain and the PY motif
Figure 1. E3 ubiquitin ligases regulating the TGF signaling pathway. HECT domain, RING type, and U-box E3 ubiquitin ligases regulate both basal levels and
activated components of the TGF signaling pathway. Black arrows illustrate TGF signal transduction. Positive (green arrows) and negative (red arrows)
regulation of TGF signaling components by the ubiquitin/proteosome pathway are also indicated.
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Table 1. E3 Ubiquitin Ligases Targeting Components of the TGFb Signaling Pathway.
E3 Ub Ligase Target Signaling
Dependence
Adaptor Modulator Effect Reference
HECT domain
Smurf1 TbRII/I A Smad6/7 [49]
BMPRII/I A Smad6/7 Inhibition of BMP signaling in Xenopus and mammalian
cells
[52]
Smad1, Smad5 B Downregulation of Smad1 target genes and secondary
axis formation
[17]
B LMP-1 Interference with Smurf/Smad interaction; enhancement
of BMP responsiveness
[78]
Smad4 A (TGFb) R/I-Smad [32]
Smad7 B p300 Acetylation decreases ubiquitination and enhances
the stability of Smad7
[75]
B HDAC1 Deacetylation enhances ubiquitination and decreases
the stability of Smad7
[43,76]
Enhancement of Smad7 Ub and promotion of renal
fibrosis by Smurf1/2
[91]
RhoA B Cdc42/PAR6/aPKC Cell migration, neurite outgrowth [106,107]
A (TGFb) PAR6/aPKC EMT [104]
B Synaptodin Interference with Smurf1/RhoA interaction; inhibition
of podocyte cell migration
[108]
MEKK2 A (BMP2) Regulation of osteoblast activity [87]
Runx2 B Smad6 Inhibition of BMP-dependent Runx2-induced transcription [83]
A (BMP2) p300 and HDAC4/5 Regulation of Runx2 ubiquitin-dependent degradation
and bone formation by dynamic acetylation
[85]
TNF Induction of Smurf1/Smurf2 expression (which mediates
Runx2 degradation) by TNF
[86]
Runx3 A (TGFb) p300 and HDAC5 Regulation of Smurf1/2–mediated Runx3 degradation
by dynamic acetylation
[84]
Smurf2 TbRII/I A Smad7 Downregulation of TGFb transcriptional activity [39]
Alk4 (ActRIB) A Smad7 FKBP12 Regulation of the duration of activin signaling [53]
Smad1, Smad2 B Robust decrease of Smad1 levels but modest decrease
of Smad2 levels; specific inhibition of Smad1 function
[18,19]
Smad2 A Downregulation of Smad2 levels; inhibition of TGFb
transcriptional activity
[18,19]
Smad4 B I-Smad [32]
Smad4 A (TGFb) R-Smad [32]
SnoN A (TGFb) Smad2 [23]
RNF11 B Blocks Smurf2-dependent inhibibion of TGFb signaling [99]
DSmurf Mad A Morphologic defects in larvae cuticle [88]
Nedd4-2 TbRII/I A Smad6/7 Downregulation of TGFb-dependent transcriptional activity [24]
Smad2 A Downregulation of TGFb-dependent transcriptional activity [24]
Smad4 B [32]
WWP1/Tiul1 TbRII/I A Smad7 Downregulation of TGFbR complex and Smad signaling;
inhibition of TGFb growth arrest
[25,26]
Smad2 A TGIF Enhancement of Smad2 turnover; inhibition of TGFb
growth arrest
[26]
Smad4 B R/I-Smad [32]
hAIP4/Itch Smad7 B Stabilization of activated TbRI/Smad7 complex; inhibition
of TGBb signaling in a Ub-independent manner
[54]
HEF1 B Smad3 Induction of HEF1 degradation through Smad3 by TGFb [58,59]





A Regulation of synaptic boutons [36]
Ectodermin Smad4 B Restriction of excessive BMP signaling in vegetal
hemisphere of Xenopus blastula; restriction of TGFb/nodal
signaling to animal pole; TGFb growth inhibition in
HepG2 cells
[37]
Cbl-b Smad2 A Increase in Smad2 phosphorylation; in vivo resistance
of Cbl-b/ T cells to TGFb
[31]
Multisubunit
APC SnoN A (TGFb) Smad3 CDH1 Regulation of cell cycle [56,57]
F-box type
SCFSkp2 Smad4 R100T B Accelerated degradation [65]
Smad4 G65V B Accelerated degradation [65]
ROC-1/SCFbTrCP1 Smad3 A p300 [27]
Smad4 A (TGFb) Jab1 Inhibition of TGFb growth arrest [33,34]
Smad4 R100T B Accelerated degradation [65]
Smad4 G65V B Accelerated degradation [65]
MFB1 DAF-7 pathway Negative regulation of Dauer formation [28]
U-box type
CHIP Smad1, Smad4 B [21]
A, interaction enhanced by signaling; B, interaction observed in basal state.
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of BMP-regulated R-Smads [17]. The cytoplasmic pool of
Smad1 and Smad2 is also regulated by Smurf2 [18,19], a
Smurf1-related E3 HECT-containing ubiquitin ligase shown to
be expressed in response to TGFb signaling [20]. For its part,
the U-box E3 ligase, CHIP (carboxyl terminus of Hsc70-
interacting protein), has also been shown to downregulate
Smad1 andSmad4 steady-state levels (Figure 1, Table 1) [21].
Ubiquitin-mediated proteosomal degradation is important
not only for controlling spurious activation of TGFb/BMP
signaling cascades but also for turning off signaling output
once the biological response has occurred. The growing
number of E3 ubiquitin ligases that are able to downregulate
activated R-Smads and their ubiquitous expression in adult
tissues reflect the importance of the proper regulation of
these signaling molecules for the maintenance of tissue
homeostasis. Degradation of phosphorylated Smad2 was
first observed in human keratinocytes, and although the
E2-conjugating enzymes UbcH5b/c and Ubc3 were impli-
cated in the transfer of ubiquitin moieties onto phospho-
Smad2, a candidate E3 ubiquitin ligase responsible for
substrate specificity had not been identified at the time [22].
In recent years, a number of E3 ubiquitin ligases have been
shown to target activated Smad2 for proteosomal degrada-
tion (Figure 1, Table 1). Although Smurf2 constitutively reg-
ulates R-Smads, the association between Smurf2 and
Smad2/3 is enhanced on TGFb stimulation, suggesting a
role for Smurf2 in the regulation of activated R-Smads
[18,23]. Two othermembers of the E3HECTdomain ubiquitin
ligase class, Nedd4-2 and WWP1/Tiul1, constitutively bind
Smad2, and as with Smurf2/Smad2 interaction, these con-
stitutive interactions are enhanced in response to an acti-
vatedTGFb type I receptor (TbRI) (Figure 1, Table 1) [24–26].
Interestingly, although Nedd4-2 enhanced the polyubiquiti-
nation and degradation of Smad2 in the presence of an
activated TbRI, the ability of WWP1/Tiul1 to target activated
Smad2 for ubiquitin-dependent proteosomal degradation is
not as clear. Although Komuro et al. [25] demonstrated that
the interaction between WWP1/Tiul1 and Smad2 was en-
hanced in the presence of activated TbRI, WWP1/Tiul1 does
not appear to promote the polyubiquitination and degradation
of activated Smad2. However, Seo et al. [26] found that
WWP1/Tiul1 was able to induce the ubiquitin-dependent
degradation of Smad2 in the presence of the transcriptional
corepressor, TGIF. Therefore, it is possible that the ability of
WWP1/Tiul1 to mediate ubiquitin-dependent proteosomal
degradation of Smad2 relies on the presence of additional
protein partners such as TGIF. Interestingly, Smurfs, Nedd4-
2, and WWP1/Tiul1 show a distinct pattern of expression in
human tissues and human carcinoma cell lines [24,25].
Although WWP1/Tiul1 protein expression levels were found
to be moderate to high in the heart, liver, skeletal muscles,
and kidneys, only low levels of Smurf1 expression were
observed in these tissues [25]. Similarly, Nedd4-2 and
Smurf2 also have distinct distribution patterns in certain
tissues such the kidneys, prostate, and testes [24].
The regulation of activated R-Smads is not exclusive to
HECT domain–containing E3 ubiquiting ligases, but may also
occur through the multisubunit RING E3 ligase, Skp-1/Cul/F-
Box (SCF) complex (Figure 1, Table 1). Roc-1, a component of
SCFFbw1a/bTrcP1, interacts with Smad3 and promotes the
SCFFbw1a/bTrcP1–dependent ubiquitination and degradation
of phosphorylated Smad3 in the cytoplasm [27]. As the inter-
action between Roc1 and Smad3 is enhanced in the presence
of the transcriptional coactivator p300, it is thought that SCF/
Roc1–mediated proteosomal degradation is necessary to
terminate Smad3 transcriptional activity [27]. Although molec-
ular targets have not been identified, MFB-1, a novel F-box–
type ubiquitin ligase, negatively regulates Dauer formation in
Caenorhabditis elegans by modulating the DAF-7/TGFb–like
signaling pathway [28]. Proteosomal degradation of activated
Smad1 has also been reported to occur through a complex
comprising the ornithine decarboxylase antizyme (Az) and
the 20S proteosome b subunit, HsN3 [29]. The targeting of
R-Smads for degradation by all three classes of E3 ubiquitin
ligases (Figure 1, Table 1) suggests that ubiquitin-dependent
proteosomal degradation is an important mechanism bywhich
a cell controls its ability to respond to both TGFb and BMP
signaling and that this occurs only when appropriate, thereby
preventing aberrant activation of cascades.
Although the polyubiquitination of R-Smads by a variety of
E3 ligases appears to negatively regulate TGFb/BMP signal-
ing, there is also emerging evidence that suggests a role for
this posttranslational modification in the enhancement of
TGFb signaling (Figure 1, Table 1). Loss of the AIP4/Itch E3
ligase in mouse embryonic fibroblasts results in resistance
to TGFb-induced cell growth inhibition [30]. Although the
turnover rate of TbRIs and Smad2 remained unchanged,
phosphorylation of Smad2 was decreased in AIP4/Itch/
cells when compared to AIP4/Itch+/ cells [30]. Biochemical
studies demonstrated that wild-type, but not catalytically
inactive, AIP4/Itch mediated the TGFb-dependent ubiqui-
tination of Smad2, as well as enhanced the interaction be-
tween Smad2 and activated TbRI [30]. Recently, the E3
ubiquitin ligase Cbl-b has also been shown to enhance
TGFb-dependent Smad2 phosphorylation in T cells [31].
Therefore, by promoting Smad2 phosphorylation, E3 ubiq-
uitin ligases may also function as positive regulators of
TGFb signaling.
Regulation of Smad4 through the Ubiquitin-Dependent
Proteosomal Pathway
Being a common intracellular effector of both the TGFb and
BMP signaling pathways, Smad4 is a critical point at which
both cascades can be modulated to maintain homeostasis.
Like R-Smads, Smad4 levels are also regulated by HECT
domain E3 ubiquitin ligases such as Smurf1, Smurf2, Nedd4-
2, and WWP1/Tiul1 (Figure 1, Table 1) [32]. However, be-
cause Smad4 lacks a PY motif, it cannot directly associate
with HECT-containing E3 ligases, but rather recruits the
enzymes through adaptors such as I-Smads and R-Smads
[32]. Consequently, mutations disrupting the interaction
between adaptors and Smad4 also interfere with the
ubiquitin-dependent degradation of Smad4 [32]. Overexpres-
sion of the Jun-activating domain binding protein 1 (Jab1), a
subunit of COP9 signalosome, promotes the interaction
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between Smad4 and the Roc1/SCFbTrCP1 complex, resulting
in the ubiquitination and proteosomal degradation of Smad4
[33,34]. Ectopic expression of oncogenic Ras has also been
shown to enhance Smad4 proteosomal degradation. How-
ever, the molecular mechanism regulating this process has
yet to be defined [35]. Drosophila Highwire (Hiw), a RING-
H2–type E3 ligase, was shown to bind the Smad4-like pro-
tein Medea (Med) in yeast-two hybrid and in vitro binding
assays [36]. Although ubiquitination and proteosomal degra-
dation of Med were not directly demonstrated, complete
genetic removal of Med in hiwmutants suppresses excessive
synaptic growth displayed in hiw single mutants. The hiw
phenotype is also suppressed in wit (a BMP type II receptor)
mutants [36]. Although the neuronal overexpression of yeast
UBP2 or Drosophila Fat Facet (Faf) deubiquitinases resulted
in synaptic overgrowth in wild-type larvae, ectopic expression
of UBP2 and Faf did not cause synaptic overexpansion in
med or wit mutants [36]. Taken together, these observations
suggest that Hiw regulates BMP signaling through Med in a
ubiquitin-dependent mechanism [36]. Recently, Ectodermin,
a single-subunit RING-type E3 ligase, was shown to prevent
excessive BMP signaling in the animal pole of Xenopus
blastula, allowing for the proper development of ectodermal
and neuronal tissues, as well as the restriction of TGFb/
nodal–mediated mesodermal induction to the vegetal hemi-
sphere of the embryo [37]. Furthermore, human Ectodermin
was also shown to restrict TGFb-induced growth arrest in
HepG2 cells [37]. Ectodermin appears to mediate these
biological responses by targeting Smad4 for ubiquitination
and proteosomal degradation, which result in the downregu-
lation of both TGFb and BMP signaling cascades [37].
In addition to being an important posttranslational modifi-
cation by which Smad4 protein levels are controlled, ubiquiti-
nation is also a mechanism by which Smad4 activity is
modulated [38]. Monoubiquitination of lysine 507 in the
MH2 domain of Smad4 enhances the association of co-Smad
with R-Smads and promotes Smad4 transcriptional activity
[38]. Therefore, as for Smad2, ubiquitination of Smad4 can
act to both positively and negatively regulate Smad4 function.
Role of Smads as Adaptor for E3 Ligases
Although Smads have clearly been shown to be substrates
for E3 ubiquitin ligases, they can also function as adaptors to
recruit ubiquitin ligases to other target proteins. This novel
role for Smadswas first described by Kavsak et al. [39]. It was
shown that, upon TGFb stimulation, the I-Smad, Smad7
interacts with Smurf2 and promotes the export of the complex
from the nucleus to the cell surface, where Smad7 acts as
a bridge to target Smurf2 to the TGFb receptor complex
(Figure 1, Table 1) [39]. Although the Smad7 MH2 domain
interacts with activated TbRI, its PY motif associates with
the WW domains of Smurf2 [17,39–41]. Furthermore, the
amino-terminal domain (NTD) of Smad7, through a leucine-
rich motif, recruits the E2-conjugating enzyme UbcH7 to the
HECT domain of Smurf2 and stimulates Smurf2 catalytic
activity [42]. Once recruited to the receptor complex, Smurf2
ubiquitinates Smad7 and promotes the degradation of both
Smad7 and the receptors [39], which occurs in the lipid-raft/
caveolar –dependent endocytic pathway [43]. Alterna-
tively, TGFb receptors also internalize through the clathrin-
dependent endocytic route where they associate with
SARA and cPML and promote Smad-dependent signaling
[11,43–47]. Because TGFb ligand does not seem to prefer-
entially target the receptors to one compartment over an-
other, it is not known what causes receptors to partition into
two different internalization compartments [43]. However, it
is likely that proper partitioning is required for the fine-tuning
of TGFb superfamily signaling. In fact, a recent study dem-
onstrated that memory of activin exposure relied on the time
spent by the activin–activin receptor signaling complex in the
clathrin-dependent endocytic pathway and was abolished
by Smad7/Smurf2 [48].
I-Smads can recruit HECT-E3 ligases other thanSmurf2 to
receptor complexes. Smad7 was also shown to associate
with Smurf1 and to recruit it to the TGFb receptor complex
(Table 1) [49]. The nuclear export of the Smad7/Smurf1
complex is mediated by chromosomal region maintenance
1 (CRM1), an importin b-related nuclear transport receptor,
and the nuclear export signal located in the HECT domain of
Smurf1 [50,51]. As with TGFb receptor complexes, Smad6
and Smad7 are capable of targeting Smurf1 to cell surface
activin and BMP receptors, and of promoting their ubiquitina-
tion and turnover [52,53]. Interestingly, the recruitment of
Smad7/Smurf1 to the activin type I receptor, ALK4 (ActRIB),
is enhanced by FKBP12, an intracellular inhibitor of TGFb
signaling [53]. Furthermore, Smad6 and Smad7 also recruit
non-Smurf HECT E3 ligases such as Nedd4-2, WWP1/Tiul1,
and human AIP4/Itch [24–26,54] to TGFb receptor com-
plexes (Figure 1, Table 1). Nedd4-2 and WWP1/Tiul1 pro-
mote the ubiquitin-dependent degradation of TGFb receptor
complexes, which results in the downregulation of TGFb-
dependent transcription and growth arrest [24–26]. Although
the mechanism by which human AIP4/Itch inhibits TGFb
signaling has not been described, it appears to be indepen-
dent of the ubiquitin-dependent proteosomal degradation of
receptors and Smads [54]. Interestingly, although human
AIP4/Itch inhibits TGFb signaling, the mouse homolog pro-
motes the phosphorylation of Smad2 and the induction of
TGFb signaling [30]. This difference may be due to tissue or
cell type–specific effects. Recent evidence also suggests
an important role for deubiquitinases such as UCH37 in
the regulation of TGFb receptor complexes [55]. A balanced
recruitment of both deubiquitinases and E3 ubiquitin li-
gases is most likely required to assure proper TGFb and
BMP responses.
In addition to I-Smads, R-Smads play an important role in
recruiting E3 ubiquitin ligases to specific substrates. Smad2
is known to recruit Smurf2 and to promote the ubiquitination
and proteosomal degradation of the transcriptional corepres-
sor SnoN (Figure 1, Table 1) [23]. Likewise, the anaphase-
promoting complex (APC) requires Smad3 as an adaptor for
the efficient ubiquitination and degradation of SnoN (Table 1)
[56,57]. The TGFb-dependent degradation of SnoN, either
through Smurf2 or APC, is thought to be a mechanism
through which the amplitude of TGFb signals is modulated
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as SnoN is itself a negative regulator of TGFb target genes.
Smad3 has also been shown to bind human AIP4/Itch and
HEF1, and to promote ubiquitin-dependent proteosomal deg-
radation of thisCas familymember (Figure 1, Table 1) [58,59].
Ubiquitination and Degradation of Oncogenic
Smad Mutants
A number of inactivating mutations have been identified in
Smad2 and Smad4 in a wide range of human carcinomas,
including colorectal, pancreatic, and lung carcinomas [3–5].
In most cases, missense and nonsense mutations cluster in
the MH2 domain of Smads and have been shown to interfere
with Smad homo-oligomerization, hetero-oligomerization,
DNA binding, and nuclear translocation [5]. However, several
mutations also affect Smad protein stability. The HCC-
derived mutation glutamine 407 to arginine (Q407R), as well
as the colorectal cancer–associated mutation leucine 369
to arginine (L369R), in the MH2 domain of Smad2 is highly
unstable and, in the case of Q407R, rapidly targets Smad2 for
ubiquitin-dependent proteosomal degradation [60,61]. A non-
sense mutation of Smad4 identified in pancreatic adenocar-
cinomas, which results in the deletion of the last 38 amino
acids of theMH2 domain, not only inhibits Smad2 recruitment
andDNAbinding but also targets Smad4 for degradation [62].
Although most Smad mutations localize to the MH2 do-
main, several mutations have also been described in theMH1
domain [38,63,64]. An arginine-to-cysteine mutation at resi-
due 133 of the MH1 domain of Smad2 leads to the increased
ubiquitination and degradation of Smad2 [63]. Likewise,
tumor-derived Smad4 L43S, G65V, R100T, and P130S
mutants all exhibit accelerated polyubiquitination and proteo-
somal degradation when compared to wild-type Smad4
[38,63,64]. A recent study shows that the SCF complex,
comprising either bTrCP-1 or Skp2 as the F-box component,
exhibits stronger binding to cancer-derived Smad4 mutants
(R100TandG65V) and catalyzes amore rapid degradation of
these mutants when compared to wild-type Smad4 (Table 1)
[65]. In summary, a number of inactivating mutations in
Smad2 and Smad4 cause accelerated ubiquitin-dependent
proteosomal degradation and likely result in aberrant TGFb
signaling, thereby promoting cancer development.
Regulation of Smads by other Posttranslational
Modifications
Protein stability and function are regulated by not only ubiq-
uitination but also a number of other ubiquitin-like modifica-
tions, such as SUMOylation, NEDDylation, and ISGylation
[66–69]. Of these three posttranslational modifications,
SUMOylation is the only one to date to be implicated in the
regulation of TGFb pathway components. SUMOylation of
target substrates appears to play an important role in the
modulation of subcellular localization, protein–protein, and
protein–DNA interactions, as well as enzyme activity and
ubiquitin-dependent degradation [66–69]. Several studies
have demonstrated that the SUMO E3 ligase PIASg (protein
inhibitor of activated STATg) interacts with Smad4 and pro-
motes its SUMOylation, which results in enhanced nuclear
accumulation, protein stability, and transcriptional activity
[70–72]. However, a recent report also demonstrates that
SUMOylation decreases the ability of Smad4 to transactivate
an artificial GAL4 promoter, suggesting that SUMOylation
may affect Smad4 transcriptional activity either positively or
negatively on different promoters [73]. PIASg has also been
shown to modify Smad3 [74]; therefore, the contradictory
effects resulting from Smad4 SUMOylation may be, in part,
explained by the simultaneous SUMOylation of Smad3.
Smad3 modification may inhibit complex formation with
Smad4 or regulate Smad3 binding to DNA, which could both
result in the downregulation of Smad4 transcriptional activity.
Alternatively, SUMOylation of Smad4 may lead to the recruit-
ment of cofactors, and the specificity of this recruitment may
be cell type–specific, which could also explain the different
effects observed on Smad4 transcriptional activity.
A number of proteins, including transcription factors and
other nuclear proteins, have been found to bemodified by the
addition of an acetyl group on the q amino group of lysine
residues. Like SUMOylation, the functional consequences of
acetylation are as diverse as increasing protein stability,
regulating protein–protein and protein–DNA interactions,
and inhibiting nuclear export. The histone acetyltransferase
p300 was shown to interact and acetylate Smad7 on two
lysine residues located in the amino-terminus of the I-Smad.
Although acetylation neither interfered with Smad7/Smurf1
complex formation nor prevented nuclear export or recruit-
ment of the complex to cell surface receptors, it did appear to
protect Smad7 from polyubiquitination [75]. Furthermore,
deacetylation of Smad7 by HDACs enhances both Smad7
polyubiquitination and turnover [76]. Taken together, these
observations suggest that a balance between acetylation and
deacetylation controls Smad7 protein stability. Acetylation of
Smad7 may protect it from premature Smurf1-mediated
degradation, allowing the recruitment of the Smad7/Smurf1
complex to cell surface receptors. However, once Smad7/
Smurf1 is recruited to the receptors, deacetylation may be
induced to promote the ubiquitination and degradation of the
TGFb receptor/Smad7/Smurf1 complex.
Biological Role of Smurfs
As negative regulators of TGFb and BMP signaling, Smurfs
have been proven to have key functions during both normal
biological responses (such as EMT, cellular migration, and
bone formation) and pathogenic processes (such as fibrosis
and cancer).
Recently, a number of in vitro and in vivo studies have
provided insight on the physiological role of the ubiquitin/
proteosome pathway in the downregulation of BMP signaling
during bone development. Ectopic expression of Smurf1
induces the proteosomal degradation of Smad5 and thereby
blocks BMP-induced osteogenic conversion of pluripotent
C2Cl2 myoblasts [77]. Recent studies have also demon-
strated that LMP-1, a LIM domain protein, inhibits Smad1
and Smad5 recruitment to Smurf1 and subsequent degrada-
tion, resulting in enhanced BMP signaling and bone nodule
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mineralization [78]. Gain-of-function studies in mice have
demonstrated that overexpression of Smurf1, under the
control of the Col1a1 promoter, leads to inhibition of osteo-
blast differentiation and reduced bone formation [79]. In
contrast, a subsequent study showed that mice in which
ectopic expression of Smurf1 was driven by the Col1a2
promoter exhibited no appreciable phenotype [80]. However,
mating Smurf1 and Smad6 transgenic animals produced
double-transgenic pups with a similar but more severe phe-
notype than that of the Smad6 transgenic mice, which in-
cluded delayed chondrocyte hypertrophy and postnatal
dwarfism with osteopenia [80]. This phenotype was due to
an impairment of BMP signaling, as decreased phospho-
Smad1, Smad5, and Smad8 were observed in trabecular
bone sections [80]. Although these studies show different
phenotypes for Smurf1 transgenic mice, likely due to the use
of different promoters to drive the overexpression of the
transgene, both studies show that Smurf1 plays a specific
role in bone formation in vivo, even if only a supportive role to
Smad6. Interestingly, Smurf1 has also been shown to regu-
late BMP-induced embryonic lung growth by downregulating
Smad1 and Smad5, suggesting that the requirement of
Smurf1 for proper BMP signaling is important for homeosta-
sis in a number of tissues [81].
The Runx family of transcription factors plays critical
functions during development and disease, and all three
Runx proteins have been shown to interact with R-Smads
and to regulate several TGFb/BMP target genes [82]. In ad-
dition, Runx proteins are themselves regulated by com-
ponents of the TGFb/BMP pathway [82]. Overexpression of
Smurf1 in 2T3 osteoblasts downregulates both Smad1 and
Runx2 protein levels and inhibits terminal osteoblast dif-
ferentiation [79]. Moreover, Smad6 recruits Smurf1, Smurf2,
and WWP1/Tiul1 to downregulate Runx2 protein levels
(Table 1) [83]. Recent evidence also suggests that, although
TGFb/BMP–dependent acetylation of Runx2 and Runx3 by
p300 counteracts Smurf1-dependent ubiquitination and deg-
radation, HDAC4- and HDAC5-mediated deacetylation of
Runx proteins appears to promote their turnover [84,85]. In-
terestingly, tumor necrosis factor promotes Runx2 ubiquitin-
dependent proteosomal degradation by upregulating Smurf1
and Smurf2 protein expression in osteoblasts [86]. There-
fore, regulation of Runx2 by Smurfs may also occur indepen-
dently of BMP signaling (Table 1).
Although overexpression studies in cell culture or gain-of-
function studies in mice have confirmed the importance of
Smurfs in Smad-dependent TGFb/BMP signaling, loss-of-
function studies have demonstrated that disruption of the
mouse Smurf1 gene does not alter Smad-dependent sig-
naling but rather affects BMP-induced osteoblast activity by
promoting the ubiquitination and destruction of MEKK2, an
activator of JNK signaling (Table 1) [87]. In Drosophila,
disruption of DSmurf activity leads to both spatial and tem-
poral expansions of phosphorylated MAD, an R-Smad–like
protein [88]. Morphologically, expansion of phospho-MAD re-
sults in the appearance of a posterior hole in the cuticle, as
well as hindgut defects, in mutant embryos (Figure 1, Table 1)
[88]. Overlapping the expression and activity of numerous E3
ubiquitin ligasesmay explain why loss of Smurf1 activity does
not significantly affect TGFb or BMP signaling in mice. How-
ever, in Drosophila, where only two E3 ubiquitin ligases
(DSmurf andHiw) have been described to negatively regulate
BMP-like signaling, disruption of DSmurf activity has more
severe effects on Smad-dependent signaling, thereby high-
lighting their pivotal role in regulating Smad function in vivo.
Although TGFbs have been shown to inhibit the prolifera-
tion of most cell types, their principal effect on mesenchymal
cells is to stimulate the proliferation and production of the
extracellular matrix, and tomediate fibrogenesis [89]. Fibrotic
diseases such as scleroderma, pulmonary fibrosis, liver cir-
rhosis, and a variety of nephropathies have been linked to
aberrant TGFb signaling [89]. Moreover, evidence suggests
that disruption of the ubiquitin/proteosome–dependent reg-
ulation of TGFb signaling promotes fibrosis. A recent study of
glomeruli isolated from rats with antithymocyte serum ne-
phritis demonstrated downregulation of Smad2 protein levels
that are inversely correlated with increased Smurf2 levels
[90]. Similarly, progressive fibrosis and enhanced TGFb
signaling in kidneys from a mouse model with progressive
tubulointerstitial fibrosis were associated with increased
Smurf1/2 protein levels and a concomitant decreased in
Smad7 protein levels (Table 1) [91]. Interestingly, gene ex-
pression profiling of scleroderma-associated lung fibroblasts
revealed increased Smad7 and Smurf2 expression in re-
sponse to TGFb stimulation [92]. Furthermore, two studies
have shown that deregulated Smad7 expression is asso-
ciated with impaired TGFb signaling in scleroderma (Ssc)
fibroblasts [93,94]. Dong et al. [93] showed that decreased
Smad7 expression in Ssc fibroblasts was associated with
increased phospho-Smad2/3 levels and enhanced TGFb-
dependent PAI-1 gene expression, suggesting that de-
creased Smad7 expression resulted in enhanced TGFb
signaling. In contrast, Asano et al. [94] reported that Ssc
fibroblasts exhibited a marked increase in Smad7 expression
and enhanced phospho-Smad2 andTbRI proteins levels, and
hypothesized that impaired Smad7-dependent degradation
of TbRI could be due to mutations in either Smad7 or Smurfs.
However, overexpression of wild-type Smad7 or Smurfs in
Ssc fibroblasts did not affect TbRI levels, suggesting that
other components of the ubiquitin/proteosome pathway may
be disrupted in Ssc fibroblasts [94]. UbcH7, which is recruited
by Smad7 to Smurf2 [42], may be mutated in Ssc fibroblasts,
and this may affect TbRI turnover. Alternatively, Caveolin-1,
which was shown to regulate Smad7/Smurf2–mediated re-
ceptor degradation [43], is downregulated in lung fibroblasts
of scleroderma patients [95], and this may be responsible for
impaired receptor degradation.
Disruption of TGFb signaling is commonly observed in
human cancers, and genetic alterations of different compo-
nents of the TGFb signaling cascade, such as the receptors
Smad2, Smad4, and Smad7, have been described in a
number of pancreatic, lung, breast, gastrointestinal, and
gynecologic cancers [2,3,5]. Being important regulators of
various components of the TGFb signaling cascade,
misregulated expression or aberrant function of E3 ubiquitin
ligases, such as Smurfs, Nedd4-2, WWP1/Tiul1, AIP4/Itch,
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Ectodermin, and the SCF complex, would gravely affect
TGFb signal transmission and potentially result in human
cancer development and progression. cDNA microarray-
based comparative genomic hybridization analysis of a set
of pancreatic carcinoma cell lines has identified Smurf1 in
DNA amplifications [96]. Likewise, reverse transcription–
polymerase chain reaction studies have shown that human
carcinoma cell lines such as colon HT-29, breast MDA-MB-
231, gastric MKN-1, and ovarian OVCAR-5 all display high
levels of one or more E3 ligases, including Smurf2, Ectoder-
min, Nedd4-2, and WWP1/Tiul1 [24,25,37]. In addition,
PRAJA, a RING-H2 E3 ubiquitin ligase that targets ELF (a
positive regulator of Smad4) for degradation is overex-
pressed in two gastric cancer cell lines (NCI-187 and SNU-
1) and likely blocks TGFb signaling by downregulating Smad4
activity through ELF [97]. Because HT-29 and MKN-1 cells
have also been described as being resistant to TGFb growth
inhibition [24], overexpression of E3 ubiquitin ligases in pro-
liferating cells likely results in downregulation of TGFb sig-
naling, and, consequently, allows these cells to escape
TGFb-induced growth inhibition and to participate in tumor
development.
Although evidence of aberrant TGFb signaling resulting
from altered E3 ubiquitin ligase activity is still scarce in human
cancers, high expression levels of Smurf2, associated with
low levels of Smad2 phosphorylation, have been detected in
esophageal squamous carcinoma [98]. This suggests that
downregulation of TGFb signaling by Smurf2 is not limited to
cell lines maintained in culture indefinitely but actually pro-
motes tumor development in humans. In contrast, upregula-
tion of TGFb signaling through downregulation of E3 ubiquitin
ligase activity is also likely to enhance the tumor promoter
activity of TGFb in later stages of the disease. RNF11, a
RING-H2 finger protein highly expressed in prostate and
invasive breast cancers, has been shown to block Smurf2-
dependent activity and to promote TGFb signaling in human
tumors [99,100]. RNF11 has also been shown to interact with
Smurf1, AIP4/Itch, and WWP1/Tiul1; thus, it may be a novel
common adaptor for E3 ubiquitin ligases that regulate TGFb
signaling [99,100]. Interestingly, recent studies have also
shown that Smurf2, upregulated by telomere attrition, uses
the p53 and Rb pathways to induce replicative senescence
through E3 ubiquitin ligase– independent activity [101].
These data also suggest a novel function for Smurf2 in tumor
development, which is independent of its role in the TGFb
signaling cascade.
The importance of TGFb signaling in cancer is not limited
to its capacity to promote growth inhibition and apoptosis in
early cancer development, but also includes its ability to
induce angiogenesis, immunosuppression, and epithelial-
to-mesenchymal (EMT) transition (Fig. 2) in later stages of
the disease [2]. EMT is a multistep process involving disso-
lution of epithelial tight junctions; disruption of adherens
junctions; cytoskeletal reorganization; loss of cell polarity;
repression of epithelial markers such as E-cadherin, ZO-1,
and b4 integrin; and upregulation of mesenchymal proteins
such as vimentin [102]. Regulation of EMT by TGFb is com-
monly thought to occur through the induction of a mesenchy-
mal gene expression profile in either a Smad-dependent or
a Smad-independent mechanism [103]. However, recent
evidence reveals a newmechanism bywhich TGFb regulates
EMT in a Smad-independent and transcription-independent
Figure 2. Smurf1-regulated RhoA degradation mediates EMT. (A) TRI is restricted to tight junctions by occludin. In tight junctions, TRI interacts with PAR6. (B)
In response to TGF, TRII is recruited to tight junctions and forms a complex with TRI and PAR6. TRII phosphorylates PAR6, thereby stimulating the
recruitment of Smurf1 to tight junctions. (C) Smurf1 promotes the ubiquitination and degradation of RhoA, resulting in tight junction dissolution and EMT.
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manner (Figure 2) [104]. In polarized epithelial cells, TbRIs
and TGFb type II receptors (TbRII) have distinct localization
patterns [104]. Although TbRII is localized to puncta distrib-
uted over the cell surface, occludin restricts TbRI to tight
junctions where it recruits PAR6 (Figure 2A) [104,105]. In
response to TGFb stimulation, TGFbRII is recruited to tight
junctions where it interacts with TbRI and directly phosphor-
ylates PAR6 (Figure 2B) [104]. TGFb-dependent phosphor-
ylation of PAR6 allows the recruitment of Smurf1, which in
turn mediates the localized ubiquitination and degradation
of RhoA, resulting in tight junction dissolution and EMT
(Figure 2C) [104]. Smurf1, through the Cdc42/PAR6/PKC~
complex, also regulates dynamic actin cytoskeletal re-
modeling by mediating localized RhoA degradation in filo-
podia and lamellipodia (Figure 3) [106]. Altogether, the
Smurf1-mediated degradation of RhoA appears to be in-
volved in multiple steps during the progression of cancer.
By contributing to the dissolution of tight junctions, Smurf1
supports the transdifferentiation of epithelial cells to a
fibroblastoid phenotype and, subsequently, by regulating
cytoskeletal remodeling, promotes cell migration. Smurf1-
dependent downregulation of RhoA has also been reported
to regulate neurite outgrowth in Neuro2A neuroblastoma
cells, as well as cell migration in kidney podocytes [107,108].
Synaptopodin, a proline-rich actin-associated protein, regu-
lates podocyte cell migration through RhoA ubiquitin–
dependent degradation by competing with Smurf1 for RhoA
binding [108]. Taken together, these data suggest that both
normal and transformed cells regulate dynamic actin cyto-
skeletal remodeling through localized Smurf1-mediated ubiq-
uitination and degradation of RhoA (Figure 3).
Conclusions
Like many other signaling cascades, the TGFb and BMP
pathways are tightly regulated at different levels by ubiquitin-
dependent proteosomal degradation. The complexity by
which the ubiquitin/proteosome pathway regulates what
appears, at first, to be a simple linear TGFb signaling path-
way is astounding. By regulating unactivated cytoplasmic
pools of R-Smads, the ubiquitin/proteosome pathway pre-
vents spurious activation of the TGFb/BMP cascade and
assures that cells remain competent to receive incoming sig-
naling cues. In addition, the targeted ubiquitination and
degradation of receptors, Smads, and transcription factors,
in response to TGFb or BMP stimulation, are a means by
which signaling is turned off. A growing list of HECT domain,
RING type, and U-box E3 ubiquitin ligases, both directly or
through adaptors, targets components of the signaling path-
way for degradation and thus assures proper signaling over a
wide variety of tissues and organs. Exciting new evidence
shows that E3 ubiquitin ligases not only act as negative
regulators but also enhance TGFb signaling by promoting
R-Smad phosphorylation. By controlling the turnover of
many tumor suppressors and oncoproteins, the ubiquitin/
proteosome pathway plays a pivotal role in the develop-
ment and progression of cancer [15,109–111]. Alteration of
ubiquitin-dependent proteosomal degradation of TGFb sig-
naling pathway components is also associated with cancer
development. Overexpression of E3 ubiquitin ligases, as de-
scribed in a number of human carcinomas and cancer cell
lines, likely contributes to cancer development by downregu-
lating TGFb pathway components, resulting in decreased
TGFb-dependent expression of genes involved in growth
Figure 3. Smurf1-dependent RhoA degradation mediates cell migration. The Cdc42/PAR6/aPKC complex recruits Smurf1 to filopodia and lamellipodia where it
locally degrades RhoA and promotes cell migration.
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inhibition and apoptosis. Adventitious expression of Smurf1
may promote cancer invasion and metastasis by potentiating
EMTand cell migration [104]. Undeniably, the pivotal role held
by E3 ubiquitin ligases in the regulation of TGFb-dependent
biological responses makes it a worthy target for the devel-
opment of small-molecule or peptide-based inhibitors for use
in future therapeutic treatments.
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